Welcome to Paid Research Studies


Browse Locations ... United States» ... West Virginia» ... Charleston





  • Conditions:   Abdominal Aortic Aneurysms;   Iliac Aneurysms;   Aortoiliac Aneurysms
    Intervention:   Device: Zenith Low Profile AAA Endovascular Graft
    Sponsor:   Cook
    Recruiting - verified August 2015

  • Condition:   Hypertension
    Interventions:   Drug: Azilsartan Medoxomil;   Drug: Losartan;   Drug: Placebo for Azilsartan Medoxomil;   Drug: Placebo for Losartan
    Sponsor:   Arbor Pharmaceuticals, Inc.
    Recruiting - verified August 2015

  • Condition:   Metastatic Renal Cell Carcinoma
    Interventions:   Drug: CRLX101 + bevacizumab;   Drug: sorafenib / everolimus / pazopanib / axitinib / bevacizumab / sunitinib / other approved drug
    Sponsor:   Cerulean Pharma Inc.
    Recruiting - verified August 2015

  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2015

  • Condition:   Cardiac Resynchronization Therapy
    Intervention:   Device: CRT-D, quadripolar coronary venous lead, defibrillation lead
    Sponsor:   Boston Scientific Corporation
    Recruiting - verified August 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Olaparib;   Drug: Placebo
    Sponsors:   AstraZeneca;   Breast International Group;   Frontier Science & Technology Research Foundation, Inc.;   NRG Oncology;   Myriad Genetics - BRACAnalysis test for FDA Premarket Approval (PMA)
    Recruiting - verified July 2015

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Conditions:   COPD;   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Aclidinium Bromide;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting - verified August 2015

  • Conditions:   Sciatica;   Lumbosacral Radiculopathy
    Intervention:   Drug: MDT-15
    Sponsor:   Medtronic Spinal and Biologics
    Recruiting - verified August 2015

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Condition:   Pneumonia, Bacterial
    Interventions:   Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
    Sponsors:   Bayer;   Nektar Therapeutics
    Recruiting - verified August 2015

  • Conditions:   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Condition:   Atrial Fibrillation
    Intervention:   Other: Patients with Atrial Fibrillation
    Sponsors:   Janssen Scientific Affairs, LLC;   Duke Clinical Research Institute
    Recruiting - verified August 2015

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
    Interventions:   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Stroke;   Atrial Fibrillation
    Intervention:  
    Sponsor:   Boehringer Ingelheim
    Recruiting - verified August 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Childhood Acute Erythroid Leukemia;   Childhood Acute Megakaryoblastic Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Fungal Infection;   Neutropenia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: caspofungin acetate;   Drug: fluconazole;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Conditions:   Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Chronic Myeloid Leukemia
    Intervention:  
    Sponsors:   Bristol-Myers Squibb;   ICON Clinical Research
    Recruiting - verified August 2015

  • Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Adenocarcinoma;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
    Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Adult B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Stage I B Lymphoblastic Lymphoma;   Stage II B Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2015

  • Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2015

  • Conditions:   Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Capecitabine;   Drug: Erlotinib Hydrochloride;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Conditions:   PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
    Interventions:   Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2015

  • Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
    Interventions:   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2015

  • Condition:   Brain Injuries
    Intervention:   Drug: NNZ-2566
    Sponsor:   Neuren Pharmaceuticals Limited
    Recruiting - verified August 2015